TEVA PHARMA INDUSTRIES LTD ADR

NYSE: TEVA (Teva Pharmaceutical Industries)

Kemas kini terakhir: semalam, 10:38AM

35.96

-0.29 (-0.80%)

  • 1H -0.80%
  • 5H 8.28%
  • 1B 16.00%
  • 6B 128.90%
  • Tahun Ke Tarikh 16.19%
  • 1T 108.95%
  • 5T 193.79%
Penutupan Terdahulu 36.25
Buka 36.18
Jumlah Dagangan 2,836,258
Purata Dagangan (3B) 11,776,652
Modal Pasaran 41,256,280,064
Harga / Pendapatan (P/E TTM) 29.72
Harga / Pendapatan (P/E Ke hadapan) 11.20
Harga / Jualan (P/S) 2.19
Harga / Buku (P/B) 5.03
Julat 52 Minggu
12.47 (-65%) — 37.35 (3%)
Tarikh Pendapatan 28 Jan 2026
Margin Keuntungan -7.74%
Margin Operasi (TTM) 18.22%
EPS Cair (TTM) -1.15
Pertumbuhan Hasil Suku Tahunan (YOY) 1.90%
Jumlah Hutang/Ekuiti (D/E MRQ) 270.20%
Nisbah Semasa (MRQ) 1.03
Aliran Tunai Operasi (OCF TTM) 1.27 B
Aliran Tunai Bebas Leveraj (LFCF TTM) 1.66 B
Pulangan Atas Aset (ROA TTM) 5.27%
Pulangan Atas Ekuiti (ROE TTM) -19.11%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - Specialty & Generic (US) Bercampur Menaik
Drug Manufacturers - Specialty & Generic (Global) Bercampur Menaik
Stok Teva Pharmaceutical Industries Menaik Menaik

AISkor Stockmoo

0.8
Konsensus Penganalisis 1.5
Aktiviti Orang Dalam NA
Volatiliti Harga -3.0
Purata Bergerak Teknikal 2.5
Osilator Teknikal 2.0
Purata 0.75

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
TEVA 41 B - 29.72 5.03
TAK 56 B 4.61% 77.03 1.08
HLN 48 B 1.08% 23.51 2.08
RDY 12 B 54.73% 18.61 2.76
ZTS 56 B 0.79% 21.38 10.22
HIMS 6 B - 46.68 10.61

Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Sektor Healthcare
Industri Drug Manufacturers - Specialty & Generic
Gaya Pelaburan Large Value
% Dimiliki oleh Institusi 67.15%

Pemilikan

Nama Tarikh Syer Dipegang
Harel Insurance Investments & Financial Services Ltd. 31 Dec 2025 44,951,773
Phoenix Financial Ltd. 30 Sep 2025 41,295,244
Menora Mivtachim Holdings Ltd. 30 Sep 2025 38,920,294
Migdal Insurance & Financial Holdings Ltd. 31 Dec 2025 37,402,212
Clal Insurance Enterprises Holdings Ltd 30 Sep 2025 31,486,683
Lingotto Investment Management Llp 30 Sep 2025 28,588,790
Rubric Capital Management Lp 30 Sep 2025 24,650,000
Pointstate Capital Lp 30 Sep 2025 20,712,398
Glenview Capital Management, Llc 30 Sep 2025 16,692,680
Duquesne Family Office Llc 30 Sep 2025 16,593,935
Altshuler Shaham Ltd 30 Sep 2025 8,297,424
Julat 52 Minggu
12.47 (-65%) — 37.35 (3%)
Julat Harga Sasaran
32.00 (-11%) — 40.00 (11%)
Tinggi 40.00 (Jefferies, 11.24%) Beli
40.00 (Scotiabank, 11.24%) Beli
40.00 (Piper Sandler, 11.24%) Beli
Median 38.00 (5.67%)
Rendah 32.00 (B of A Securities, -11.01%) Beli
Purata 37.25 (3.59%)
Jumlah 8 Beli
Harga Purata @ Panggilan 31.57
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Barclays 30 Jan 2026 38.00 (5.67%) Beli 34.08
09 Dec 2025 35.00 (-2.67%) Beli 28.56
Scotiabank 29 Jan 2026 40.00 (11.23%) Beli 33.07
05 Dec 2025 35.00 (-2.67%) Beli 28.46
Truist Securities 29 Jan 2026 38.00 (5.67%) Beli 33.07
Jefferies 06 Jan 2026 40.00 (11.23%) Beli 32.11
Piper Sandler 22 Dec 2025 40.00 (11.23%) Beli 31.21
Goldman Sachs 19 Dec 2025 35.00 (-2.67%) Beli 30.35
08 Dec 2025 31.00 (-13.79%) Beli 28.33
JP Morgan 16 Dec 2025 35.00 (-2.67%) Beli 30.10
06 Nov 2025 28.00 (-22.14%) Beli 24.46
B of A Securities 09 Dec 2025 32.00 (-11.01%) Beli 28.56
Papar semua

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
28 Jan 2026 Pengumuman Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential
28 Jan 2026 Pengumuman Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential
27 Jan 2026 Pengumuman Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’
27 Jan 2026 Pengumuman Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’
14 Jan 2026 Pengumuman AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine
14 Jan 2026 Pengumuman AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine
11 Jan 2026 Pengumuman Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
11 Jan 2026 Pengumuman Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
11 Jan 2026 Pengumuman Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
11 Jan 2026 Pengumuman Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation
11 Jan 2026 Pengumuman Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation
07 Jan 2026 Pengumuman Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
05 Jan 2026 Pengumuman Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference
05 Jan 2026 Pengumuman Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference
24 Dec 2025 Pengumuman S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive
24 Dec 2025 Pengumuman S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive
23 Dec 2025 Pengumuman Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026
19 Dec 2025 Pengumuman Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
19 Dec 2025 Pengumuman Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
19 Dec 2025 Pengumuman Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
17 Dec 2025 Pengumuman Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA
16 Dec 2025 Pengumuman Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)
12 Dec 2025 Pengumuman Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026
12 Dec 2025 Pengumuman Teva Releases Q4 2025 Aide Memoire
12 Dec 2025 Pengumuman Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026
12 Dec 2025 Pengumuman Teva Releases Q4 2025 Aide Memoire
09 Dec 2025 Pengumuman Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
09 Dec 2025 Pengumuman Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
25 Nov 2025 Pengumuman Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference
25 Nov 2025 Pengumuman Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®
25 Nov 2025 Pengumuman Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®
21 Nov 2025 Pengumuman Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December
21 Nov 2025 Pengumuman Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December
19 Nov 2025 Pengumuman Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma’s Biggest Challenges
19 Nov 2025 Pengumuman Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma’s Biggest Challenges
12 Nov 2025 Pengumuman Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates
07 Nov 2025 Pengumuman AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living
07 Nov 2025 Pengumuman AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living
05 Nov 2025 Pengumuman Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS
05 Nov 2025 Pengumuman Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS
Papar semua
Purata Hasil Dividen 5T 0.00%
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
27 Nov 2017 06 Nov 2017 12 Dec 2017 0.085 Tunai
25 Aug 2017 - 14 Sep 2017 0.07225 Tunai
01 Jun 2017 - 22 Jun 2017 0.289 Tunai
28 Feb 2017 - 20 Mar 2017 0.289 Tunai
01 Dec 2016 - 20 Dec 2016 0.289 Tunai
18 Aug 2016 - 08 Sep 2016 0.289 Tunai
20 May 2016 - 07 Jun 2016 0.289 Tunai
25 Feb 2016 - 14 Mar 2016 0.289 Tunai
13 Nov 2015 - 03 Dec 2015 0.289 Tunai
18 Aug 2015 - 03 Sep 2015 0.289 Tunai
15 May 2015 - 04 Jun 2015 0.289 Tunai
17 Feb 2015 - 03 Mar 2015 0.293636 Tunai
13 Nov 2014 - 02 Dec 2014 0.269593 Tunai
19 Aug 2014 - 04 Sep 2014 0.291112 Tunai
16 May 2014 - 02 Jun 2014 0.29777 Tunai
20 Feb 2014 - 10 Mar 2014 0.293019 Tunai
18 Nov 2013 - 03 Dec 2013 0.277541 Tunai
16 Aug 2013 - 03 Sep 2013 0.273656 Tunai
16 May 2013 - 03 Jun 2013 0.268249 Tunai
19 Feb 2013 - 07 Mar 2013 0.266857 Tunai
13 Nov 2012 - 03 Dec 2012 0.202399 Tunai
13 Aug 2012 - 04 Sep 2012 0.208281 Tunai
17 May 2012 - 04 Jun 2012 0.196042 Tunai
23 Feb 2012 - 13 Mar 2012 0.197212 Tunai
10 Nov 2011 - 07 Dec 2011 0.17539 Tunai
09 Nov 2011 - 07 Dec 2011 0.171904 Tunai
04 Aug 2011 - 25 Aug 2011 0.196304 Tunai
03 Aug 2011 - 25 Aug 2011 0.199624 Tunai
19 May 2011 - 07 Jun 2011 0.199925 Tunai
10 Feb 2011 - 07 Mar 2011 0.216813 Tunai
08 Nov 2010 - 06 Dec 2010 0.173008 Tunai
02 Aug 2010 - 26 Aug 2010 0.166994 Tunai
10 May 2010 - 04 Jun 2010 0.163153 Tunai
19 Feb 2010 - 17 Mar 2010 0.164033 Tunai
06 Nov 2009 - 04 Dec 2009 0.125431 Tunai
03 Aug 2009 - 27 Aug 2009 0.124804 Tunai
08 May 2009 - 03 Jun 2009 0.120261 Tunai
23 Feb 2009 - 19 Mar 2009 0.111992 Tunai
07 Nov 2008 - 05 Dec 2008 0.09309 Tunai
01 Aug 2008 - 27 Aug 2008 0.10421 Tunai
13 May 2008 - 05 Jun 2008 0.11255 Tunai
12 May 2008 - 05 Jun 2008 0.10919 Tunai
18 Feb 2008 - 13 Mar 2008 0.10429 Tunai
15 Feb 2008 - 13 Mar 2008 0.10174 Tunai
02 Nov 2007 - 28 Nov 2007 0.084 Tunai
10 Aug 2007 - 06 Sep 2007 0.08015 Tunai
10 May 2007 - 05 Jun 2007 0.0833 Tunai
16 Feb 2007 - 15 Mar 2007 0.07866 Tunai
10 Nov 2006 - 06 Dec 2006 0.06569 Tunai
11 Aug 2006 - 08 Sep 2006 0.06434 Tunai
12 May 2006 - 07 Jun 2006 0.06257 Tunai
06 Mar 2006 - 30 Mar 2006 0.06072 Tunai
10 Nov 2005 - 07 Dec 2005 0.05188 Tunai
11 Aug 2005 - 07 Sep 2005 0.05431 Tunai
05 May 2005 - 01 Jun 2005 0.0559 Tunai
17 Feb 2005 - 17 Mar 2005 0.0559 Tunai
09 Nov 2004 - 06 Dec 2004 0.0414 Tunai
09 Aug 2004 - 07 Sep 2004 0.0401 Tunai
10 May 2004 - 07 Jun 2004 0.0768 Tunai
20 Feb 2004 - 22 Mar 2004 0.0781 Tunai
13 Nov 2003 - 12 Dec 2003 0.0587 Tunai
08 Aug 2003 - 08 Sep 2003 0.0596 Tunai
08 May 2003 - 06 Jun 2003 0.0581 Tunai
24 Feb 2003 - 24 Mar 2003 0.0546 Tunai
07 Nov 2002 - 06 Dec 2002 0.0738 Tunai
19 Aug 2002 - 16 Sep 2002 0.0738 Tunai
20 May 2002 - 17 Jun 2002 0.0701 Tunai
15 Feb 2002 - 18 Mar 2002 0.0772 Tunai
16 Nov 2001 - 17 Dec 2001 0.0531 Tunai
20 Aug 2001 - 17 Sep 2001 0.0498 Tunai
17 May 2001 - 15 Jun 2001 0.0486 Tunai
08 Mar 2001 - 06 Apr 2001 0.0477 Tunai
16 Nov 2000 - 15 Dec 2000 0.0407 Tunai
24 Aug 2000 - 21 Sep 2000 0.0415 Tunai
19 May 2000 - 19 Jun 2000 0.0405 Tunai
17 Feb 2000 - 27 Mar 2000 0.0838 Tunai
04 Nov 1999 - 30 Nov 1999 0.0529 Tunai
18 Aug 1999 - 13 Sep 1999 0.0527 Tunai
21 May 1999 - 15 Jun 1999 0.054 Tunai
08 Mar 1999 - 30 Mar 1999 0.055 Tunai
20 Nov 1998 - 11 Dec 1998 0.053 Tunai
21 Aug 1998 - 11 Sep 1998 0.058 Tunai
21 May 1998 - 22 Jun 1998 0.0639 Tunai
12 Mar 1998 - 31 Mar 1998 0.0649 Tunai
20 Nov 1997 - 09 Dec 1997 0.0666 Tunai
25 Aug 1997 - 11 Sep 1997 0.0667 Tunai
23 May 1997 - 12 Jun 1997 0.069 Tunai
07 Mar 1997 - 26 Mar 1997 0.0695 Tunai
20 Nov 1996 - 09 Dec 1996 0.0468 Tunai
26 Aug 1996 - 12 Sep 1996 0.0492 Tunai
23 May 1996 - 12 Jun 1996 0.0477 Tunai
07 Mar 1996 - 26 Mar 1996 0.0504 Tunai
20 Nov 1995 - 07 Dec 1995 0.0485 Tunai
14 Aug 1995 - 30 Aug 1995 0.0488 Tunai
17 May 1995 - 07 Jun 1995 0.051 Tunai
07 Mar 1995 - 04 Apr 1995 0.0512 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2017 0.735 4 3.88
2016 1.16 4 3.19
2015 1.16 4 1.77
2014 1.15 4 2.00
2013 1.09 4 2.71
2012 0.804 4 2.15
2011 1.16 6 2.87
2010 0.667 4 1.28
2009 0.482 4 0.86
2008 0.625 6 1.47
2007 0.326 4 0.70
2006 0.253 4 0.82
2005 0.218 4 0.51
2004 0.236 4 0.79
2003 0.231 4 0.82
2002 0.295 4 1.53
2001 0.199 4 1.29
2000 0.207 4 1.13
1999 0.215 4 2.40
1998 0.240 4 4.72
1997 0.272 4 4.60
1996 0.194 4 3.09
1995 0.200 4 3.44
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda